Prime赛道 meets Top Talent: Bio-automation Emerges with New Force!

With the development of industries such as precision medicine and in vitro diagnostics, there is a rising demand for life science equipment among biopharmaceutical companies, government agencies, medical institutions, testing and inspection organizations, and research institutions. This is particularly evident in sample preparation equipment, where many traditional devices are being replaced by high-efficiency, automated, and intelligent sample preparation systems.

Pipetting is the primary and foundational step in all life science experiments. Pipetting accuracy has a significant impact on experimental results, and as detection scenarios expand, the requirements for pipetting precision continue to increase. Automated liquid handling workstations are fully automatic, high-precision liquid processing systems. Compared to traditional pipetting tools, they can automatically perform high-precision liquid handling tasks such as gradient dilution, pipetting, and liquid pooling. They also enable efficient and precise detection of target analytes, significantly reducing labor costs and human error while improving overall efficiency.

The life sciences automation sector, which includes liquid handling workstations, is a high-barrier, high-potential industry with significant room for future growth.On Sunday, December 18, at 13:30, Hanzandi will launch its new CANTUS FLEX, an independent 8-channel liquid handling workstation. Concurrently, VCBeat has invited industry companies, experts, and investors to jointly discuss “new technologies, new scenarios, and new trends in the field of life science automation.”

Scan the QR code to schedule a live stream

Xu Chengqi

School of Life Science and Technology, Huazhong University of Science and Technology| Associate Professor, Doctoral Supervisor

Committee Member of the Branch of Basic and Translational Medicine, Chinese Geriatrics Society; Council Member of the Hubei Genetics Society. Employing approaches such as genome-wide association studies and high-throughput sequencing technologies, has discovered and identified multiple novel pathogenic and susceptibility genes for cardiovascular diseases, including coronary heart disease, atrial fibrillation, and hypertension. Has published numerous papers in prestigious international journals, including Nature Genetics, Clinical Translational Medicine, Cardiovascular Research, Stroke, and Circulation: Cardiovascular Genetics; and has served as Principal Investigator on three projects funded by the National Natural Science Foundation of China.

Li Zhe

Proxima Ventures | Partner

Mr. Li Zhe currently serves as a Partner at Proxima Ventures. Proxima Fund focuses on investing in innovative medical technologies and currently manages multiple RMB and USD funds, with its investment portfolio covering medical devices and biotechnology. The firm has assembled an investment team with international industry backgrounds and extensive clinical networks, boasting exceptional track records in both investment and entrepreneurship. Proxima Fund believes that active and effective collaboration with founding teams not only delivers substantial economic returns but also brings about meaningful improvements to public health. Mr. Li has led investments in and served as a director for numerous innovative medical technology companies, including HanZanDi, RuiDi Bio, WeiKe Medical, DeYun KangRui, JieYi Bio, MoZhuo Bio, DaWan Bio, and WeiYou Gene.

Gloria Li

Shanghai Hanzandi Life Technology Co., Ltd. | CEO

CEO of Shanghai HanZanDi Life Technology Co., Ltd.; Master’s degree in Neuropharmacology from Shanghai Jiao Tong University; Doctorate in Healthcare Management from the University of Montpellier; EMBA from ISC Paris Business School. Previously worked at Thermo Fisher Scientific, overseeing clinical sequencing business in Greater China; subsequently served as General Manager for China at Bionano Genomics and ADI; formerly held the position of National Sales Director at Tecan.

Xu Liping

Shanghai HanZandi Life Technology Co., Ltd. | Senior Product Manager

With over a decade of extensive experience in marketing and product management within the biotechnology and healthcare industries, having held positions at companies such as Beckman Coulter and Thermo Fisher Scientific.

[About Proxima Ventures]

Proxima Ventures is a specialized investment firm focused on innovative medical technologies and disruptive biotechnologies, dedicated to serving exceptional innovative healthcare enterprises with significant growth potential. Managed and operated by a professional team with extensive experience in the medical industry, Proxima Ventures boasts diverse and international expertise, professional backgrounds, and industry networks. The firm currently manages multiple RMB and USD funds. Proxima Ventures has established a leading healthcare entrepreneurship ecosystem, facilitating connections between its portfolio companies and high-quality clinical and industrial resources, achieving remarkable experience and results.

[About Hanzandi]

Shanghai BioHandler Life Science Technology Co., Ltd., abbreviated as BioHandler, is a leading high-tech enterprise in China engaged in the research and development, manufacturing, sales, and service of intelligent automated equipment and system solutions for life sciences and medical diagnostics.

The founding core team members of HanZanDi possess over a decade of experience in life science product development and backgrounds in biology. They have deep expertise in life science marketing management and business model innovation, hold numerous core patented technologies, and adhere to an ultimate innovative design philosophy characterized by modularity, intelligence, and simplicity. They design and develop intelligent products with independent intellectual property rights, integrate advantageous resources, and provide excellent products and services for the entire global life science workflow. HanZanDi is able to communicate with scientists in a unified life science language, accurately translate and transform life science needs, realize the vision of "becoming the leader in intelligent solutions for the entire life science workflow," and fulfill the mission of "letting technology celebrate life and fulfilling the promise of science."

Guided by the organizational competencies of “passion, innovation, collaboration, learning agility, independent judgment, and altruism,” and anchored in the methodological values of “first-principles thinking and structured reasoning,” Hanzandi puts into practice the philosophies of “simplifying the known, exploring the unknown” and “excellence through differentiation.” Committed to independent innovation and shouldering the responsibility of revitalizing China’s domestic industries, Hanzandi aims to fundamentally reshape the global market landscape, elevate the global reputation of Chinese innovation, and establish itself as a premier international brand.

[About VCBeat]

VCBeat, founded in 2014, is a novel industry service provider that leverages data as its foundation, research as its core, and brand media as its connector to facilitate the precise aggregation of industry resources and accelerate the growth of industry innovators. It offers services such as brand communication, research consulting, data monitoring, and resource/project matchmaking to enterprises, government industrial parks, investment institutions, and other stakeholders across the industry chain.